No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
|Market Cap||1.8 billion|
|Outstanding Shares||1.1 billion|
|Sector Name||Health Care|
|Country Short Name||US|
|Announcement Earnings||2023-11-14 13:00:00+00:00|
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Please sign up and become a member to view all risk profiles.
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.